Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSTI-500 in Prader-Willi Syndrome
NCT07348601Phase 2Recruiting
- Sponsor
- ConSynance Therapeutics
- Start
- May 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CSTI-500 in Prader-Willi syndrome (PWS), sponsored by ConSynance Therapeutics. Started May 2026; status: recruiting.
02
Drugs
CSTI-500
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT07348601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348601.